Birte Yding Glenthoej
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Birte Yding Glenthoej has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Egill Rostrup
Center for Neuropsychiatric Schizophrenia Research (CNSR) & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Copenhagen University Hospital – Mental Health Services CPH
44 shared publications - Bjørn Hylsebeck Ebdrup
Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, Glostrup, Copenhagen University Hospital - Mental Health Services CPH, Glostrup, Denmark
35 shared publications Bob Oranje
Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) and Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Centre Glostrup, Glostrup, Denmark
28 shared publicationsBirgitte Fagerlund
Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark
26 shared publicationsBjørn H. Ebdrup
Center for Neuropsychiatric Schizophrenia Research, Mental Health Center Glostrup, Copenhagen University Hospital – Mental Health Services CPH, Copenhagen, Denmark
24 shared publications- Birgitte Fagerlund
University of Copenhagen
21 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Springer Nature in Translational Psychiatry
Glutamate levels in antipsychotic-free, first-episode psychosis: a 7-tesla MRS study across five brain regions
- 27 September 2026
- Published by Springer Nature in Translational Psychiatry
Open AccessGlutamate levels in antipsychotic-free, first-episode psychosis: a 7-tesla MRS study across five brain regions
- Open Access
- 2 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Fish oil-derived fatty acids during pregnancy and risk of neurodevelopmental disorders in children at age 10 - A randomized controlled trial
Fish oil-derived omega-3 fatty acids (ꙍ-3 FA), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are critical for early brain development, but evidence of causal effects from supplementation during pregnancy is limited. In the prospective COPSAC2010 cohort of 700 mother-child pairs, we investigated whether i) maternal DHA + EPA blood concentrations in mid-pregnancy and ii) fish oil supplementation in a randomized trial in late pregnancy influence neurodevelopmental outcomes at age 10. Maternal blood DHA + EPA concentrations were measured at 24 weeks gestation, followed by randomization to 2.4 g daily fish oil (37% DHA, 55% EPA) or placebo until one-week postpartum. Psychopathology was assessed in the children at age 10 using the Kiddie Schedule for Affective Disorders and Schizophrenia -Present and Lifetime version and parental-rated questionnaires Statistical analyses included logistic and linear regression models. Higher maternal DHA + EPA concentrations were associated with reduced ADHD risk (OR 0.71, p = 0.03) and ADHD symptom load (β = -1.14, p < 0.001) in unadjusted analyses but not after confounder adjustment (OR 0.82, p = 0.24; β = -0.49, p = 0.21). Similar trends were observed for autistic traits (β = -1.96, [-1.11; -0.24] p = 0.01), but not significant after confounder adjustment. Fish oil supplementation showed no significant reduction in ADHD (OR 0.79, p = 0.37) or ASD risk (OR 0.56, p = 0.42). A secondary analysis suggested a protective effect for ADHD Predominantly Inattentive Presentation, although it did not hold significance after correction for multiple testing (OR 0.41; p = 0.03; FDRp=0.12). Thus, potential effects on inattentive ADHD symptoms should be explored in future studies.
- 2 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessFish oil-derived fatty acids during pregnancy and risk of neurodevelopmental disorders in children at age 10 - A randomized controlled trial
Fish oil-derived omega-3 fatty acids (ꙍ-3 FA), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are critical for early brain development, but evidence of causal effects from supplementation during pregnancy is limited. In the prospective COPSAC2010 cohort of 700 mother-child pairs, we investigated whether i) maternal DHA + EPA blood concentrations in mid-pregnancy and ii) fish oil supplementation in a randomized trial in late pregnancy influence neurodevelopmental outcomes at age 10. Maternal blood DHA + EPA concentrations were measured at 24 weeks gestation, followed by randomization to 2.4 g daily fish oil (37% DHA, 55% EPA) or placebo until one-week postpartum. Psychopathology was assessed in the children at age 10 using the Kiddie Schedule for Affective Disorders and Schizophrenia -Present and Lifetime version and parental-rated questionnaires Statistical analyses included logistic and linear regression models. Higher maternal DHA + EPA concentrations were associated with reduced ADHD risk (OR 0.71, p = 0.03) and ADHD symptom load (β = -1.14, p < 0.001) in unadjusted analyses but not after confounder adjustment (OR 0.82, p = 0.24; β = -0.49, p = 0.21). Similar trends were observed for autistic traits (β = -1.96, [-1.11; -0.24] p = 0.01), but not significant after confounder adjustment. Fish oil supplementation showed no significant reduction in ADHD (OR 0.79, p = 0.37) or ASD risk (OR 0.56, p = 0.42). A secondary analysis suggested a protective effect for ADHD Predominantly Inattentive Presentation, although it did not hold significance after correction for multiple testing (OR 0.41; p = 0.03; FDRp=0.12). Thus, potential effects on inattentive ADHD symptoms should be explored in future studies.
- 4 April 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (8) , 4716-4726
Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis
The Clinical High Risk (CHR) state for psychosis is consistently associated with widespread cortical thinning. However, the underlying mechanisms driving this neuroanatomical phenotype remain poorly understood. Here, we integrated the ENIGMA CHR Working Group's large pooled dataset (N = 1782 CHR, N = 1333 healthy controls) with an open-source PET molecular atlas to identify, for the first time, potential neurochemical drivers of cortical thinning associated with psychosis risk, transition, and its core symptoms. Using multilinear model analysis, we show that local chemoarchitecture significantly explains CT differences associated with CHR case-control status, the severity of negative symptoms, and future psychosis transition after excluding medication confounds. PET-based maps of dopamine, GABA, glutamate, serotonin, and norepinephrine consistently emerged as the strongest predictors of lower CT in CHR and psychosis transition (total dominance range: 62-69% and 58-87%, respectively), with contributions of monoamine systems being especially sensitive to medication exposure (8-23% change in dominance range). Negative symptom-associated cortical thinning was best explained by PET-based maps of dopamine, histamine, serotonin and opioid systems (total dominance range: 60-81%), with contributions of histamine being sensitive to medication exposure (9-19% change in dominance range). Combined, these results uniquely identify specific neurochemical systems - particularly monoaminergic, glutamatergic, and GABAergic pathways - as key molecular mechanisms associated with cortical thinning in people at high risk of developing psychosis.
- 4 April 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (8) , 4716-4726
Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis
The Clinical High Risk (CHR) state for psychosis is consistently associated with widespread cortical thinning. However, the underlying mechanisms driving this neuroanatomical phenotype remain poorly understood. Here, we integrated the ENIGMA CHR Working Group's large pooled dataset (N = 1782 CHR, N = 1333 healthy controls) with an open-source PET molecular atlas to identify, for the first time, potential neurochemical drivers of cortical thinning associated with psychosis risk, transition, and its core symptoms. Using multilinear model analysis, we show that local chemoarchitecture significantly explains CT differences associated with CHR case-control status, the severity of negative symptoms, and future psychosis transition after excluding medication confounds. PET-based maps of dopamine, GABA, glutamate, serotonin, and norepinephrine consistently emerged as the strongest predictors of lower CT in CHR and psychosis transition (total dominance range: 62-69% and 58-87%, respectively), with contributions of monoamine systems being especially sensitive to medication exposure (8-23% change in dominance range). Negative symptom-associated cortical thinning was best explained by PET-based maps of dopamine, histamine, serotonin and opioid systems (total dominance range: 60-81%), with contributions of histamine being sensitive to medication exposure (9-19% change in dominance range). Combined, these results uniquely identify specific neurochemical systems - particularly monoaminergic, glutamatergic, and GABAergic pathways - as key molecular mechanisms associated with cortical thinning in people at high risk of developing psychosis.
- Open Access
- 6 January 2026
- Published by Springer Nature in Schizophrenia
- Vol. 12 (1)
Whole-brain functional connectivity predicts ultra-high risk for psychosis status and level of functioning
Resting-state functional magnetic resonance imaging (rs-fMRI) has offered insights into the neural mechanisms underlying psychosis, particularly when associated with clinically relevant features. 102 individuals at ultra-high risk for psychosis (UHR) and 105 matched healthy controls (HC) aged 18–40 underwent clinical and cognitive assessments and rs-fMRI at baseline. Using a recently developed prediction-based extension of the network-based statistics (NBS-predict), incorporating nested cross-validation, we tested the predictive power of functional connectivity estimated from rs-fMRI data, investigating diagnostic classification and prediction of level of functioning, estimated IQ, and UHR-symptoms. Hyper-connectivity predicted group with a classification accuracy of 0.58, p = 0.043, and hypo-connectivity predicted group with a classification accuracy of 0.59, p = 0.018. Hyper-connectivity in UHR-individuals was observed primarily in interhemispheric and cortico-thalamic connections, within networks that predicted poorer levels of functioning across groups. Hypo-connectivity in UHR-individuals was observed mainly in thalamic connections with posterior cingulate cortex, frontal medial, and precuneus, within networks that predicted higher level of functioning across groups. Post hoc analyses identified a significant groupwise interaction effect on the association between functional connectivity and level of functioning (ρ = 0.34, p < 0.001), with main nodes in the frontal medial regions connected across hemispheres. Within-group, no connections predicted level of functioning or UHR-symptoms. Whole-brain functional connectivity predicted UHR-status in hyper- and hypo-connected networks, with thalamus as a central integrative hub across networks. Connections that predicted level of functioning across groups were equivalent to the connections predicting UHR-status, hence capturing a neural correlate to a key clinical component of the UHR-status.
- 6 January 2026
- Published by Springer Nature in Schizophrenia
- Vol. 12 (1)
Open AccessWhole-brain functional connectivity predicts ultra-high risk for psychosis status and level of functioning
Resting-state functional magnetic resonance imaging (rs-fMRI) has offered insights into the neural mechanisms underlying psychosis, particularly when associated with clinically relevant features. 102 individuals at ultra-high risk for psychosis (UHR) and 105 matched healthy controls (HC) aged 18–40 underwent clinical and cognitive assessments and rs-fMRI at baseline. Using a recently developed prediction-based extension of the network-based statistics (NBS-predict), incorporating nested cross-validation, we tested the predictive power of functional connectivity estimated from rs-fMRI data, investigating diagnostic classification and prediction of level of functioning, estimated IQ, and UHR-symptoms. Hyper-connectivity predicted group with a classification accuracy of 0.58, p = 0.043, and hypo-connectivity predicted group with a classification accuracy of 0.59, p = 0.018. Hyper-connectivity in UHR-individuals was observed primarily in interhemispheric and cortico-thalamic connections, within networks that predicted poorer levels of functioning across groups. Hypo-connectivity in UHR-individuals was observed mainly in thalamic connections with posterior cingulate cortex, frontal medial, and precuneus, within networks that predicted higher level of functioning across groups. Post hoc analyses identified a significant groupwise interaction effect on the association between functional connectivity and level of functioning (ρ = 0.34, p < 0.001), with main nodes in the frontal medial regions connected across hemispheres. Within-group, no connections predicted level of functioning or UHR-symptoms. Whole-brain functional connectivity predicted UHR-status in hyper- and hypo-connected networks, with thalamus as a central integrative hub across networks. Connections that predicted level of functioning across groups were equivalent to the connections predicting UHR-status, hence capturing a neural correlate to a key clinical component of the UHR-status.
- Open Access
- 22 October 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (3) , 1707-1722
Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study
Brain network architecture is anticipated to influence future grey matter loss in individuals at Clinical High Risk (CHR) for psychosis. However, existing studies on grey matter structural network properties in CHR are scarce and constrained by small sample sizes. Here, we examined network topology differences comparing a) CHR versus healthy controls (HC); b) CHR who transitioned to psychosis (CHR-T) versus those who did not (CHR-NT); and c) different subsyndromes. We included structural scans from 1842 CHR individuals and 1417 HC individuals from 31 sites within the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium. At the global level, CHR individuals exhibited lower structural covariance (q < 0.001; Cohen’s d = 0.164) and less optimal structural network configuration than HC (lower global efficiency and clustering coefficient, d = 0.100,0.087, qs <= 0.027). Though no global difference between CHR-T and CHR-NT, network distinctiveness of the frontal and temporal surface area networks was higher in CHR-T than CHR-NT (d = 0.223,0.237) and HC (d = 0.208,0.219) (qs < 0.001). Network distinctiveness of the frontal cortical thickness network was lower in CHR-T (d = 0.218, q < 0.001) than CHR-NT and HC (d = 0.165, q < 0.001). Importantly, higher network distinctiveness was associated with worse positive symptoms in CHR-NT (frontal surface area, q = 0.008, R2 = 0.013) and at trend with worse negative symptoms in CHR-T (frontal thickness, q = 0.063, R2 = 0.049). Further, the brief intermittent psychotic syndrome subgroup showed more severe network alterations. Together, brain structural networks inform symptoms and the risk of transition to psychosis in CHR individuals.
- 22 October 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (3) , 1707-1722
Open AccessStructural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study
Brain network architecture is anticipated to influence future grey matter loss in individuals at Clinical High Risk (CHR) for psychosis. However, existing studies on grey matter structural network properties in CHR are scarce and constrained by small sample sizes. Here, we examined network topology differences comparing a) CHR versus healthy controls (HC); b) CHR who transitioned to psychosis (CHR-T) versus those who did not (CHR-NT); and c) different subsyndromes. We included structural scans from 1842 CHR individuals and 1417 HC individuals from 31 sites within the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium. At the global level, CHR individuals exhibited lower structural covariance (q < 0.001; Cohen’s d = 0.164) and less optimal structural network configuration than HC (lower global efficiency and clustering coefficient, d = 0.100,0.087, qs <= 0.027). Though no global difference between CHR-T and CHR-NT, network distinctiveness of the frontal and temporal surface area networks was higher in CHR-T than CHR-NT (d = 0.223,0.237) and HC (d = 0.208,0.219) (qs < 0.001). Network distinctiveness of the frontal cortical thickness network was lower in CHR-T (d = 0.218, q < 0.001) than CHR-NT and HC (d = 0.165, q < 0.001). Importantly, higher network distinctiveness was associated with worse positive symptoms in CHR-NT (frontal surface area, q = 0.008, R2 = 0.013) and at trend with worse negative symptoms in CHR-T (frontal thickness, q = 0.063, R2 = 0.049). Further, the brief intermittent psychotic syndrome subgroup showed more severe network alterations. Together, brain structural networks inform symptoms and the risk of transition to psychosis in CHR individuals.
- Open Access
- 15 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 5652-5663
Cerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition
Although emerging evidence supports glutamatergic dysfunction in schizophrenia, clinical trials with glutamatergic compounds have overall been negative. This may be due to changes in glutamate levels during the course of illness. To address this, we measured glutamate levels in dorsal anterior cingulate cortex (dACC) and left thalamus in 57 initially antipsychotic-naïve patients with first-episode psychosis (FEP) aged 22.6 ± 5.0 years (58% females) and 55 healthy controls (HC) on a 3T MR scanner at baseline, after six weeks (48 FEP and 53 HC), six months (37 FEP and 49 HC), and two years (35 FEP and 45 HC). Positive and negative symptoms and cognitive function in tests of attention and spatial working memory were assessed at all visits. Linear mixed models were used in statistical analyses. We found lower glutamate levels in dACC in FEP (p = 0.03) that was associated with deficits in attention at all visits (p < 0.05). Thalamic glutamate levels did not differ between groups, but higher levels were related to more pronounced positive symptoms at all visits (p = 0.02). The relation between thalamic glutamate levels and negative symptoms was altered over time (negative symptoms*time: p = 0.003) due to a significant positive association after two years (p = 0.04) but not at other visits. For other metabolites, thalamic NAA were lower in FEP (p = 0.04) and total creatine was increased after 6 weeks treatment (p = 0.01), whereas dACC glx levels were lower after two years (p = 0.02). The results suggest that greater positive symptom severity is related to higher thalamic glutamate levels and cognitive deficits to lower dACC glutamate levels during the first two years of illness. Furthermore, higher thalamic glutamate levels after two years are associated with more severe negative symptomatology. Findings imply that glutamatergic compounds decreasing thalamic and increasing dACC glutamate levels may be beneficial in FEP over the first two years of illness.
- 15 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 5652-5663
Open AccessCerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition
Although emerging evidence supports glutamatergic dysfunction in schizophrenia, clinical trials with glutamatergic compounds have overall been negative. This may be due to changes in glutamate levels during the course of illness. To address this, we measured glutamate levels in dorsal anterior cingulate cortex (dACC) and left thalamus in 57 initially antipsychotic-naïve patients with first-episode psychosis (FEP) aged 22.6 ± 5.0 years (58% females) and 55 healthy controls (HC) on a 3T MR scanner at baseline, after six weeks (48 FEP and 53 HC), six months (37 FEP and 49 HC), and two years (35 FEP and 45 HC). Positive and negative symptoms and cognitive function in tests of attention and spatial working memory were assessed at all visits. Linear mixed models were used in statistical analyses. We found lower glutamate levels in dACC in FEP (p = 0.03) that was associated with deficits in attention at all visits (p < 0.05). Thalamic glutamate levels did not differ between groups, but higher levels were related to more pronounced positive symptoms at all visits (p = 0.02). The relation between thalamic glutamate levels and negative symptoms was altered over time (negative symptoms*time: p = 0.003) due to a significant positive association after two years (p = 0.04) but not at other visits. For other metabolites, thalamic NAA were lower in FEP (p = 0.04) and total creatine was increased after 6 weeks treatment (p = 0.01), whereas dACC glx levels were lower after two years (p = 0.02). The results suggest that greater positive symptom severity is related to higher thalamic glutamate levels and cognitive deficits to lower dACC glutamate levels during the first two years of illness. Furthermore, higher thalamic glutamate levels after two years are associated with more severe negative symptomatology. Findings imply that glutamatergic compounds decreasing thalamic and increasing dACC glutamate levels may be beneficial in FEP over the first two years of illness.
- Open Access
- 12 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (3) , 1231-1240
Interrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naïve psychosis patients and the association to initial treatment response
Preclinical evidence points to disturbances in neural networks in psychosis involving interrelations between dopaminergic-, GABAergic- and glutamatergic neurotransmitter systems. In support, we have previously shown that aberrant interrelations between these neurotransmitters, in contrast to individual transmitter systems, can separate antipsychotic-naïve first-episode psychotic patients (AN-FEP) from healthy controls (HC). Here, we characterized neurotransmitter interrelations, examined their association with treatment response, and explored the effect of treatment on the interrelations. Sixty participants (29 AN-FEP and 31 HC) underwent dynamic [18F]-DOPA PET with arterial blood sampling to measure dopamine synthesis (DS) (k 3 ) in nucleus accumbens (NAcc) and magnetic resonance spectroscopy (MRS) to estimate levels of glutamate (Glu) in anterior cingulate cortex (ACC) and thalamus, and gamma-aminobutyric-acid (GABA) in ACC. A subgroup of the patients was re-scanned after six weeks antipsychotic monotherapy with aripiprazole (PET: 10 AN-FEP; MRS: 27 AN-FEP; 30 HC). Psychopathology was assessed at both visits. Multiple linear regression models and linear mixed models were used to analyze data. We found a negative association between k 3 (dependent variable) and GABA in HC (β = −0.15, p = 0.03) and a positive association in patients (β = 0.15, p = 0.04). The aberrant relationship between k 3 and GABA was driven by the group-GABA interaction (p = 0.002) and related to treatment response (p = 0.02). No significant group interactions were found for the interrelations between k 3 and Glu, but a positive association was found between k 3 and Glu in thalamus (p = 0.04) in both groups and the association decreased after treatment in AN-FEP (p = 0.01). The data show that DS in NAcc and GABA levels in ACC are inversely interrelated in AN-FEP, and that the degree of abnormality predicts treatment effect. Moreover, antipsychotic treatment alters the relationship between dopaminergic activity in NAcc and Glu levels in thalamus. The findings suggest that combined instead of single neurotransmitter disturbances should be considered when novel therapeutics are developed for schizophrenia. Clinical trial registration: The Pan European Collaboration on Antipsychotic Naïve Schizophrenia II (PECANSII) study, ClinicalTrials.gov Identifier: NCT02339844. https://www.clinicaltrials.gov/study/NCT02339844 .
- 12 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (3) , 1231-1240
Open AccessInterrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naïve psychosis patients and the association to initial treatment response
Preclinical evidence points to disturbances in neural networks in psychosis involving interrelations between dopaminergic-, GABAergic- and glutamatergic neurotransmitter systems. In support, we have previously shown that aberrant interrelations between these neurotransmitters, in contrast to individual transmitter systems, can separate antipsychotic-naïve first-episode psychotic patients (AN-FEP) from healthy controls (HC). Here, we characterized neurotransmitter interrelations, examined their association with treatment response, and explored the effect of treatment on the interrelations. Sixty participants (29 AN-FEP and 31 HC) underwent dynamic [18F]-DOPA PET with arterial blood sampling to measure dopamine synthesis (DS) (k 3 ) in nucleus accumbens (NAcc) and magnetic resonance spectroscopy (MRS) to estimate levels of glutamate (Glu) in anterior cingulate cortex (ACC) and thalamus, and gamma-aminobutyric-acid (GABA) in ACC. A subgroup of the patients was re-scanned after six weeks antipsychotic monotherapy with aripiprazole (PET: 10 AN-FEP; MRS: 27 AN-FEP; 30 HC). Psychopathology was assessed at both visits. Multiple linear regression models and linear mixed models were used to analyze data. We found a negative association between k 3 (dependent variable) and GABA in HC (β = −0.15, p = 0.03) and a positive association in patients (β = 0.15, p = 0.04). The aberrant relationship between k 3 and GABA was driven by the group-GABA interaction (p = 0.002) and related to treatment response (p = 0.02). No significant group interactions were found for the interrelations between k 3 and Glu, but a positive association was found between k 3 and Glu in thalamus (p = 0.04) in both groups and the association decreased after treatment in AN-FEP (p = 0.01). The data show that DS in NAcc and GABA levels in ACC are inversely interrelated in AN-FEP, and that the degree of abnormality predicts treatment effect. Moreover, antipsychotic treatment alters the relationship between dopaminergic activity in NAcc and Glu levels in thalamus. The findings suggest that combined instead of single neurotransmitter disturbances should be considered when novel therapeutics are developed for schizophrenia. Clinical trial registration: The Pan European Collaboration on Antipsychotic Naïve Schizophrenia II (PECANSII) study, ClinicalTrials.gov Identifier: NCT02339844. https://www.clinicaltrials.gov/study/NCT02339844 .
- Open Access
- 23 May 2025
- Published by Springer Nature in Research Square
Fish Oil-Derived Fatty Acids in Pregnancy and Brain Metabolism in Middle Childhood: Results From a Randomized Controlled Trial
Maternal blood levels of polyunsaturated fatty acids (PUFA) during pregnancy have been associated with brain health outcomes in offspring, but causal effects of PUFA on brain metabolism is unexplored. We examined the effect of maternal PUFA supplementation on brain metabolism in children at age 10, measured as cerebral blood flow (CBF), oxygen consumption (CMRO₂), and brain lactate concentration. We used data from the COPSAC2010 cohort (n = 700), where pregnant women were randomized to PUFA supplementation or placebo. At age 10, the children underwent psychopathological and cognitive assessments as well as MRI scans to obtain CBF, CMRO₂, and brain lactate. We estimated the effect of maternal PUFA intake on brain metabolism and examined the associations between those metabolic measurements with psychopathological symptoms and cognitive outcomes in the offspring. Lastly, we investigated the association of age with brain metabolic outcomes by comparing with data from adult participants from five previous studies. 487 children (51.7% male, 10.3 ± 0.32 years old) underwent 3 Tesla MRI scan. Children whose mothers received PUFA supplementation exhibited significantly lower CBF and CMRO₂; however, these parameters were not associated with psychopathology or cognition. The age-related analysis, with additional data of 248 adults, showed that higher age was associated with lower CBF, CMRO₂, and lactate concentration. Our findings suggest that maternal PUFA supplementation influences brain maturation in the offspring at age 10, although PUFA supplementation does not directly translate into psychopathological status and cognitive performance. Our results highlight the need for further large-scale studies on maternal nutrition and brain development.
- 23 May 2025
- Published by Springer Nature in Research Square
Open AccessFish Oil-Derived Fatty Acids in Pregnancy and Brain Metabolism in Middle Childhood: Results From a Randomized Controlled Trial
Maternal blood levels of polyunsaturated fatty acids (PUFA) during pregnancy have been associated with brain health outcomes in offspring, but causal effects of PUFA on brain metabolism is unexplored. We examined the effect of maternal PUFA supplementation on brain metabolism in children at age 10, measured as cerebral blood flow (CBF), oxygen consumption (CMRO₂), and brain lactate concentration. We used data from the COPSAC2010 cohort (n = 700), where pregnant women were randomized to PUFA supplementation or placebo. At age 10, the children underwent psychopathological and cognitive assessments as well as MRI scans to obtain CBF, CMRO₂, and brain lactate. We estimated the effect of maternal PUFA intake on brain metabolism and examined the associations between those metabolic measurements with psychopathological symptoms and cognitive outcomes in the offspring. Lastly, we investigated the association of age with brain metabolic outcomes by comparing with data from adult participants from five previous studies. 487 children (51.7% male, 10.3 ± 0.32 years old) underwent 3 Tesla MRI scan. Children whose mothers received PUFA supplementation exhibited significantly lower CBF and CMRO₂; however, these parameters were not associated with psychopathology or cognition. The age-related analysis, with additional data of 248 adults, showed that higher age was associated with lower CBF, CMRO₂, and lactate concentration. Our findings suggest that maternal PUFA supplementation influences brain maturation in the offspring at age 10, although PUFA supplementation does not directly translate into psychopathological status and cognitive performance. Our results highlight the need for further large-scale studies on maternal nutrition and brain development.
- Open Access
Cerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition
Although emerging evidence supports glutamatergic dysfunction in schizophrenia, clinical trials with glutamatergic compounds have overall been negative. This may be due to changes in glutamate levels during the course of illness. To address this, we measured glutamate levels in dorsal anterior cingulate cortex (dACC) and left thalamus in 57 initially antipsychotic-naïve patients with first-episode psychosis (FEP) aged 22.6 ± 5.0 years (58% females) and 55 healthy controls (HC) on a 3T MR scanner at baseline, after six weeks (48 FEP and 53 HC), six months (37 FEP and 49 HC), and two years (35 FEP and 45 HC). Positive and negative symptoms and cognitive function in tests of attention and spatial working memory were assessed at all visits. Linear mixed models were used in statistical analyses. We found lower glutamate levels in dACC in FEP (p=0.03) that was associated with deficits in attention at all visits (p<0.05). Thalamic glutamate levels did not differ between groups, but higher levels were related to more pronounced positive symptoms at all visits (p=0.02). The relation between thalamic glutamate levels and negative symptoms was altered over time (negative symptoms*time: p=0.003) due to a significant positive association after two years (p=0.04) but not at other visits. For other metabolites, thalamic NAA were lower in FEP (p=0.04) and total creatine was increased after 6 weeks treatment (p=0.01), whereas dACC glx levels were lower after two years (p=0.02). The results suggest that greater positive symptom severity is related to higher thalamic glutamate levels and cognitive deficits to lower dACC glutamate levels during the first two years of illness. Furthermore, higher thalamic glutamate levels after two years are associated with more severe negative symptomatology. Findings imply that glutamatergic compounds decreasing thalamic and increasing dACC glutamate levels may be beneficial in FEP over the first two years of illness.
Open AccessCerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition
Although emerging evidence supports glutamatergic dysfunction in schizophrenia, clinical trials with glutamatergic compounds have overall been negative. This may be due to changes in glutamate levels during the course of illness. To address this, we measured glutamate levels in dorsal anterior cingulate cortex (dACC) and left thalamus in 57 initially antipsychotic-naïve patients with first-episode psychosis (FEP) aged 22.6 ± 5.0 years (58% females) and 55 healthy controls (HC) on a 3T MR scanner at baseline, after six weeks (48 FEP and 53 HC), six months (37 FEP and 49 HC), and two years (35 FEP and 45 HC). Positive and negative symptoms and cognitive function in tests of attention and spatial working memory were assessed at all visits. Linear mixed models were used in statistical analyses. We found lower glutamate levels in dACC in FEP (p=0.03) that was associated with deficits in attention at all visits (p<0.05). Thalamic glutamate levels did not differ between groups, but higher levels were related to more pronounced positive symptoms at all visits (p=0.02). The relation between thalamic glutamate levels and negative symptoms was altered over time (negative symptoms*time: p=0.003) due to a significant positive association after two years (p=0.04) but not at other visits. For other metabolites, thalamic NAA were lower in FEP (p=0.04) and total creatine was increased after 6 weeks treatment (p=0.01), whereas dACC glx levels were lower after two years (p=0.02). The results suggest that greater positive symptom severity is related to higher thalamic glutamate levels and cognitive deficits to lower dACC glutamate levels during the first two years of illness. Furthermore, higher thalamic glutamate levels after two years are associated with more severe negative symptomatology. Findings imply that glutamatergic compounds decreasing thalamic and increasing dACC glutamate levels may be beneficial in FEP over the first two years of illness.
- Open Access
- 10 April 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (4) , e1004454
Maternal dietary patterns, breastfeeding duration, and their association with child cognitive function and head circumference growth: A prospective mother–child cohort study
Background: Early life is a critical period for neurodevelopment, where factors such as maternal nutrition and breastfeeding duration significantly impact the growth of head circumference and cognitive development in children. Our study aimed to explore the associations between maternal dietary patterns during pregnancy, duration of breastfeeding, and their impacts on child head circumference and cognitive outcomes. Methods and findings: Our study utilised data from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort, which enrolled 700 mother–child pairs between 2008 and 2010 with 86% clinical follow-up at age 10. Pregnancy dietary patterns, described as ‘Varied’ and ‘Western,’ were derived from food frequency questionnaires and used to model quantitative metabolite scores via sparse partial least squares modelling of blood metabolome data. Cognitive development was assessed using the Bayley Scales of Infant Development at 2.5 years and the Wechsler Intelligence Scale for Children at age 10. Head circumference was measured from 20 weeks gestation to 10 years, and calibrated using related anthropometric measures. Growth trajectories were evaluated using linear mixed models and latent class trajectory models. Parental and child genetic influences for cognition and head circumference were controlled by including polygenic risk scores derived from genomic data. We found that a Western dietary pattern during pregnancy was associated with lower cognitive scores at age 2.5 (β −1.24 [−2.16, −0.32], p = 0.008) and reduced head circumference growth (p-interaction < 0.0001). We found that a Varied dietary pattern during pregnancy was associated with higher estimated intelligence quotient (IQ) at age 10 (β 1.29 [0.27, 2.3], p = 0.014). Additionally, head circumference growth was associated with higher cognitive scores at age 10 (β 3.40 [1.21, 5.60], p = 0.002), and it partly mediates the association between the Varied dietary pattern and estimated IQ (proportion mediated 13.5% [0.01, 0.71], p = 0.034). Extended breastfeeding duration was also independently associated with increased head circumference growth (p-interaction < 0.0001). These patterns and correlations were consistent even after adjusting for potential confounders and accounting for genetic influences. Conclusions: Our findings reveal that a Western dietary pattern during pregnancy is associated with lower cognitive scores at age 2.5 and decreased head circumference growth, suggesting potential adverse impacts on early neurodevelopment. Conversely, a Varied dietary pattern is linked with a higher estimated IQ at age 10, with head circumference growth contributing to this positive outcome. These findings highlight the critical role of maternal nutrition during pregnancy, and duration of breastfeeding, in promoting optimal neurodevelopmental outcomes. Effective public health strategies should therefore focus on enhancing maternal dietary practices to support better cognitive and physical development in children.
- 10 April 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (4) , e1004454
Open AccessMaternal dietary patterns, breastfeeding duration, and their association with child cognitive function and head circumference growth: A prospective mother–child cohort study
Background: Early life is a critical period for neurodevelopment, where factors such as maternal nutrition and breastfeeding duration significantly impact the growth of head circumference and cognitive development in children. Our study aimed to explore the associations between maternal dietary patterns during pregnancy, duration of breastfeeding, and their impacts on child head circumference and cognitive outcomes. Methods and findings: Our study utilised data from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort, which enrolled 700 mother–child pairs between 2008 and 2010 with 86% clinical follow-up at age 10. Pregnancy dietary patterns, described as ‘Varied’ and ‘Western,’ were derived from food frequency questionnaires and used to model quantitative metabolite scores via sparse partial least squares modelling of blood metabolome data. Cognitive development was assessed using the Bayley Scales of Infant Development at 2.5 years and the Wechsler Intelligence Scale for Children at age 10. Head circumference was measured from 20 weeks gestation to 10 years, and calibrated using related anthropometric measures. Growth trajectories were evaluated using linear mixed models and latent class trajectory models. Parental and child genetic influences for cognition and head circumference were controlled by including polygenic risk scores derived from genomic data. We found that a Western dietary pattern during pregnancy was associated with lower cognitive scores at age 2.5 (β −1.24 [−2.16, −0.32], p = 0.008) and reduced head circumference growth (p-interaction < 0.0001). We found that a Varied dietary pattern during pregnancy was associated with higher estimated intelligence quotient (IQ) at age 10 (β 1.29 [0.27, 2.3], p = 0.014). Additionally, head circumference growth was associated with higher cognitive scores at age 10 (β 3.40 [1.21, 5.60], p = 0.002), and it partly mediates the association between the Varied dietary pattern and estimated IQ (proportion mediated 13.5% [0.01, 0.71], p = 0.034). Extended breastfeeding duration was also independently associated with increased head circumference growth (p-interaction < 0.0001). These patterns and correlations were consistent even after adjusting for potential confounders and accounting for genetic influences. Conclusions: Our findings reveal that a Western dietary pattern during pregnancy is associated with lower cognitive scores at age 2.5 and decreased head circumference growth, suggesting potential adverse impacts on early neurodevelopment. Conversely, a Varied dietary pattern is linked with a higher estimated IQ at age 10, with head circumference growth contributing to this positive outcome. These findings highlight the critical role of maternal nutrition during pregnancy, and duration of breastfeeding, in promoting optimal neurodevelopmental outcomes. Effective public health strategies should therefore focus on enhancing maternal dietary practices to support better cognitive and physical development in children.